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Question: In people with non-specific low back pain (LBP), what are the effects of photobiomodulation
therapy (PBMT) on pain, disability and other outcomes when compared with no intervention, sham PBMT
and other treatments, and when used as an adjunct to other treatments? Design: Systematic review of
randomised trials with meta-analysis. Participants: People with acute/subacute or chronic non-specific LBP.
Interventions: Any type of PBMT (laser class I, II and III and light-emitting diodes) compared with no
treatment, sham PBMT and other types of treatment, or used as an adjunct to another treatment. Outcome
measures: Pain intensity, disability, overall improvement, quality of life, work absence and adverse effects.
Results: Twelve randomised controlled trials were included (pooled n = 1,046). Most trials had low risk of
bias. Compared with sham PBMT, the effect of PBMT on pain and disability was clinically unimportant in
people with acute/subacute or chronic LBP. In people with chronic LBP, there was no clinically important
difference between the effect of PBMT and the effect of exercise on pain or disability. Although benefits were
observed on some other outcomes, these estimates were imprecise and/or based on low-quality evidence.
PBMT was estimated to reduce pain (MD 211.20, 95% CI 220.92 to 21.48) and disability (MD 211.90, 95%
CI 217.37 to 26.43) more than ultrasound, but these confidence intervals showed important uncertainty
about whether the differences in effect were worthwhile or trivial. Conversely, PBMT was estimated to
reduce pain (MD 19.00, 95% CI 9.49 to 28.51) and disability (MD 17.40, 95% CI 8.60 to 26.20) less than Tecar
(Energy Transfer Capacitive and Resistive) therapy, with marginal uncertainty that these differences in effect
were worthwhile. Conclusion: Current evidence does not support the use of PBMT to decrease pain and
disability in people with non-specific LBP. Registration: CRD42018088242. [Tomazoni SS, Almeida MO,
Bjordal JM, Stausholm MB, Machado CSM, Leal-Junior ECP, Costa LOP (2020) Photobiomodulation
therapy does not decrease pain and disability in people with non-specific low back pain: a systematic
review. Journal of Physiotherapy 66:155–165]
© 2020 Australian Physiotherapy Association. Published by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Low back pain (LBP) is a highly prevalent condition worldwide1,2
and the leading cause of years lived with disability.3 In most cases,
the specific pathological cause remains unidentified; therefore, the
term non-specific LBP is commonly used for such cases.4 Many non-
pharmacological therapies are available for the treatment of LBP,
which aim to reduce pain and disability.1 Among these options,
photobiomodulation therapy (PBMT) has been recently recom-
mended by the American College of Physicians clinical practice
guidelines for the treatment of LBP.5 However, the strength of this
recommendation was supported by only three existing randomised
controlled trials.6–8n. Published by Elsevier B.V. This isA new terminology established in 2015 defined PBMT as a non-
thermal and non-ionising light therapy applied in the form of light
amplification by the stimulated emission of radiation (laser), light-
emitting diodes (LEDs), and/or broadband irradiation in the visible
and infrared spectra.9 PBMT acts through the interaction between the
light emitted and photoreceptors present in mitochondria in different
tissues.9,10 This interaction triggers positive effects such as stimula-
tion of cellular metabolism and negative effects such as inhibition of
cellular metabolism.11 Various PBMT parameters can be applied but
doses appear to need to be inside a therapeutic window to trigger
positive effects.12–14 A recently published editorial15 highlighted that
although there is a guideline with recommended PBMT doses for the
treatment of musculoskeletal disorders and tendinopathies,16 thean open access article under the CC BY-NC-ND license (http://creativecommons.org/
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may lead to misleading conclusions.15 Trials that presumably used
inadequate PBMT doses have failed to get positive biological re-
sponses in conditions like carpal tunnel syndrome and osteoar-
thritis.17,18 On the other hand, there is evidence that PBMT was
effective in the treatment of several musculoskeletal disorders such
as neck and shoulder pain, temporomandibular disorders and ten-
dinopathies.19–25 Laboratory studies have suggested that PBMT can
reduce inflammation, limit tissue damage processes and promote
myotube proliferation.25
The effectiveness of light-based therapy in people with LBP has
been summarised in three systematic reviews.26–28 The first one was
published in 200826 when PBMT was known as low-level laser
therapy. This systematic review included seven randomised trials
that compared the effectiveness of PBMT against no treatment,
placebo or other interventions in people with acute, subacute and
chronic LBP. The authors concluded that there was insufficient data
for conclusive recommendations on the clinical effects of PBMT in
people with LBP. The second systematic review was published
in 201527 and also included seven randomised trials. The third
systematic review was published in 201628 and retrieved 15 rand-
omised trials. The last two systematic reviews27,28 compared light-
based therapy only against placebo in people with chronic LBP. In
addition, the authors claimed that they included only randomised
trials investigating the effects of low-level laser therapy. However,
one trial29 was misclassified as low-level laser therapy instead of
high-intensity laser therapy and was mistakenly included in both
systematic reviews.27,28 In addition, the 2016 systematic review28
included several randomised trials investigating the effects of laser
acupuncture. Thus, both reviews27,28 do not pertain to the effects of
PBMT in people with LBP because although laser acupuncture and
high-intensity laser therapy are light-based therapies, neither of
these is currently considered as PBMT. High-intensity laser therapy
promotes thermal effects, whereas PBMT, by definition, is a non-
thermal process.9,10 In addition, laser acupuncture is the photonic
stimulation of acupuncture points aiming to obtain similar effects as
those obtained using acupuncture with needles, along with the
added benefits of light stimulation.30
Recommendations about the use of PBMT in clinical practice
should preferably be supported by a high-quality systematic review.
The last high-quality systematic review on this topic was published in
2008 and new trials31–35 have been conducted since then. Therefore,
an updated systematic review regarding the effects of PBMT on LBP is
necessary in order to provide the best available evidence to clinicians
and people. It is important to summarise all the available evidence
about the effects of PBMT in people with acute, subacute and chronic
LBP. In addition, it is important to summarise the evidence regarding
the effectiveness of PBMT compared with other types of
interventions.
Therefore, this systematic review was conducted to summarise
the effects of PBMT on pain and disability in people with non-specific
LBP, when: compared with control conditions (such as minimal
intervention, placebo and no treatment); compared with other in-
terventions; and used as an adjunct to other treatments. Further-
more, a subgroup analysis was conducted to investigate the adequacy
of PBMT dosage based on doses recommended by the World Asso-
ciation for Photobiomodulation Therapy (WALT).16
Therefore, the research question for this systematic review was:
In people with non-specific low back pain, what are the effects of
photobiomodulation therapy on pain and disability when
compared with control conditions, when compared with other
interventions and when used as an adjunct to other treatments?intervention)
 PBMTwith another intervention versus the same intervention
 PBMT versus another active intervention
LBP = low back pain, LED = light-emitting diode, PBMT =
photobiomodulation therapy.Methods
This systematic review followed the recommendations of the
Cochrane Handbook of Systematic Reviews.36Identification and selection of studies
Five databases were searched for eligible trials without language
restriction from inception until May 2019: MEDLINE (Ovid), Embase,
Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative
Index to Nursing and Allied Health Literature (CINAHL) and Physio-
therapy Evidence Database (PEDro). Manual searches were conducted
of the reference lists of prior systematic reviews on this topic and any
trials included in the present review. Clinical trial records databases
and grey literature (eg, congress proceedings) were also searched. The
detailed search strategies are described in Appendix 1 on the
eAddenda.
Two independent reviewers independently screened all titles and
abstracts retrieved by the searches to identify potentially eligible
trials. Any record that was judged potentially eligible by at least one
of the reviewers was retrieved in full text and assessed by both re-
viewers against the eligibility criteria. A third reviewer resolved any
disagreements.
Types of participants
The inclusion criteria for participants are presented in Box 1.
Participants were not excluded by gender. Any duration of LBP was
acceptable and categorised as acute/subacute (, 12 weeks) or chronic
( 12 weeks).37 Trials that presented a mixed sample (acute/subacute
and chronic together) were included only when the data were pre-
sented separately. Moreover, we excluded trials in which the partic-
ipants presented LBP due to a specific pathology such as infection,
inflammatory diseases, rheumatoid arthritis, nerve root compromise,
fractures or neoplasms.
Types of interventions
Trials were only included if they estimated the effects of any type
of PBMT (laser class I, II or III or LED), including all wavelengths. Other
light-based therapy such as laser acupuncture and high-intensity
laser (laser class IV) were not included because they are not
PBMT.9,10,30 The eligible comparators are listed in Box 1.
Types of outcomes measures
The primary outcomes were: pain intensity, measured by the Pain
Numerical Rating scale38 or another validated quantitative measure-
ment method; and disability, measured by the Roland-Morris
Disability Questionnaire,39,40 Oswestry Disability Questionnaire41 or
another validated quantitative measurement method. These
Research 157outcomes reflect the most recent core outcome set for people with
LBP.42,43
The secondary outcomes were: overall improvement or satisfac-
tion with treatment, as reported by participants or therapists, or
measured by the Global Perceived Effect scale38 or other validated
instruments; quality of life reported by questionnaires such as the SF-
12,44 SF-36,45 or EuroQoL;46 return to work, work absence, or days of
reduced activities;47 and adverse effects.Assessment of characteristics of the studies
Two reviewers independently extracted the following data from
the included trials: bibliometric data, sample size, characteristics of
the participants (age, gender and duration of pain), and details of the
interventions, outcome measures and results. A third reviewer
resolved any disagreements. When necessary, the authors of the
included trials were contacted to provide additional information or
trial data. In the data extraction phase, all PBMT characteristics and
dosages were checked for accuracy by recalculating them as recom-
mended by the WALT,48 based on the data available in the trials or
through e-mail correspondence with the authors.Risk of bias
The risk of bias in the included trials was rated using the PEDro
scale, which also rates the completeness of statistical reporting.49 The
total PEDro score ranges from 0 to 10, calculated by summing the
number of criteria achieved with the exception of criterion 1, which is
not considered in the final score.49 Two independent reviewers
evaluated any included trial with the PEDro scale, unless a score was
already provided on the PEDro webpage (then this score was
selected). The trials were considered as ‘low risk’ of bias if they had a
score of  6 points. Trials with scores , 6 points were considered as
having ‘high risk’ of bias.50Data analysis
Measures of treatment effect
The effects of the interventions on (sub)acute and chronic LBP
were analysed separately. Data were calculated in relation to the
short term (outcomes assessed closest to 4 weeks after random-
isation), medium term (outcomes assessed closest to 6 months after
randomisation) and long term (outcomes assessed closest to 1 year
after randomisation).51 Results from an intention-to-treat analysis
approach were used whenever possible.
All continuous outcome data were converted to a common scale
ranging from 0 to 100 and synthesised using the mean difference
(MD) method with its respective 95% confidence intervals. The
standard deviations for analysis were extracted or if necessary esti-
mated from other variance data using the methods described in the
Cochrane Handbook.36 Categorical outcomes data were reported as
relative risk (RR) with 95% confidence interval. All possible meta-
analyses were conducted using systematic review softwarea. When
there were trials with sufficient homogeneity in the comparison, a
meta-analysis was performed using the random effects model to
calculate the pooled treatment effect with the 95% confidence
interval.
The size of treatment effects were categorised as: small (ie, MD ,
10% of the scale; RR . 0.8 or , 1.25), moderate (MD 10 to 20% of the
scale; RR 1.25 to 2.0, or 0.5 to 0.8) or large (MD . 20% of the scale, RR
. 2.0 or, 0.5).52 The effect was considered clinically important when
the effect size was at least moderate.53,54Dealing with missing data
Missing standard deviations were calculated based on t-values
and p-values for differences in means.36 When only the mean and
standard deviation of changes from baseline were reported, these
values were used in the analysis.Assessment of heterogeneity
The presence of between-trial statistical heterogeneity was
assessed using the I2 statistic. The quality of evidence was down-
graded for inconsistency if considerable between-group statistical
heterogeneity (I2 . 50%) was detected.
Data synthesis
The overall quality of the evidence for each outcome was evalu-
ated using the Grading of Recommendations, Development and
Evaluation (GRADE) system,36 regardless of whether there was suf-
ficient information to summarise the data in a quantitative analysis.
The following five factors were considered for classifying the quality
of the evidence, where for each factor not met, the quality of evidence
was reduced by one level (from high to moderate, low or very
low):36,55 risk of bias (. 25% of the trials included in the comparison
were classified as high risk of bias); inconsistency (I2 . 50%): indi-
rectness (. 50% of the participants were not related to the trial’s
target audience); imprecision (, 400 participants in the comparison
for continuous outcomes and . 300 participants for categorical
outcomes); and publication bias (evaluated using a funnel plot when
. 10 trials in the same comparison). Single trial comparisons (, 400
participants for continuous outcomes and , 300 participants for
dichotomous outcomes) were considered to be inconsistent and
imprecise, providing ‘low-quality evidence’, which could be down-
graded to ‘very low-quality evidence’ if limitations were identified
regarding risk of bias.52,54
The quality of the evidence was categorised as follows. Evidence
was high quality if the results were consistent in  75% of the par-
ticipants, with low risk of bias, without publication bias, and with
consistent, direct, and precise data; further research is unlikely to
change the estimate or confidence in such results. Evidence was
moderate quality when one of the five classification factors above was
not met; further research is likely to change the estimated effect and
impact confidence in the effect. Evidence was low quality when two
of the five classification factors were not met; future research is likely
to change the estimated effect and will have a significant impact on
confidence in the effect. Evidence was very low quality when three of
the five classification factors were not met; any estimate of effect is
very uncertain.
Subgroup analysis
We performed the subgroup analysis for adequacy of PBMT
dosage based on the dosages recommended by WALT.16 WALT rec-
ommends irradiating the lumbar spine with the following doses:  4
joules per treatment point (4 to 8 points or cm2) using 780 to 860 nm
laser and  1 joules per treatment point (4 points or cm2) using 904
nm laser.16 According to these recommendations the included trials
were divided into two subgroups: assumed adequate dose or
assumed inadequate dose (not mentioned in guidelines or low dose).
Sensitivity analysis
When enough data were available, sensitivity analyses were
conducted to assess the influence of trials with high risk of bias and
unpublished trials on the estimated effect of treatment for primary
outcomes.56Results
Flow of studies through the review
The initial electronic database search identified a total of 1,977
records, of which 40 appeared potentially eligible after screening by
title and abstract. Assessment of full text identified 12 eligible tri-
als6–8,31–35,57–60 (pooled n = 1,046), among which 10
trials6–8,31–33,35,57–59 provided data that were amenable to meta-
analysis (pooled n = 680). The flow diagram of the full selection
process and the inclusion of trials is presented in Figure 1. Articles
excluded by full-text evaluation are presented with the reasons for
exclusion in Table 2 on the eAddenda.
Records identified through searching of 
electronic databases (n = 1,977)
Medline (n = 153)
EMBASE (n = 809)
CENTRAL (n = 373)
CINAHL (n = 569)
PEDro (n = 73)
Records excluded (n = 1,937)
duplicates (n = 550)
ineligible based on title and abstract (n = 1,387)
Full-text articles assessed for eligibility (n = 40)
Excluded after full text evaluation (n = 28)
high-intensity laser (n = 8)
not randomised (n = 5)
abstract only (n = 5)
ineligible therapy (n = 3)
ineligible participants (n = 3)
PBMT versus PBMT (n = 1)
no separate analysis for LBP participants (n = 1) 
uncontrolled study (n = 1)
journal and manuscript unavailable (n = 1)
Trials included in qualitative synthesis (n = 12)
Trials included in meta-analysis (n = 10)
Figure 1. Flow of trials through the review.
PBMT = photobiomodulation therapy, LBP = low back pain.
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Risk of bias
The results of risk of bias assessment are presented in Table 1. The
PEDro score of the included trials ranged from 2 to 9 points (mean 6.6
points, SD 1.8). Random allocation was applied in every trial. How-
ever, 75% and 67% of the trials did not performed intention-to-treat
analysis and concealed allocation, respectively. Moreover, the thera-
pists and participants were not blinded in 58% and 50% of the trials,
respectively. In contrast, the assessors were blinded in 83% of theTable 1
















Ay31 N Y N Y Y N
Basford8 Y Y N Y Y Y
Djavid57 Y Y Y Y N N
Gur58 Y Y N Y N N
Hsieh32 Y Y Y Y Y N
Klein59 Y Y N Y Y Y
Longo60 N Y N N N Y
Nambi33 Y Y N Y N N
Notarnicola34 Y Y N Y N N
Soriano7 N Y N Y Y Y
Tantawy35 Y Y Y Y N N
Toya6 N Y Y N Y Y
N = no, Y = yes.
a Relates to external validity and therefore does not contribute to the total score.trials. The baseline scores were similar in 83% of the trials, follow-up
was adequate in 67% of the trials, between-group comparisons were
reported in 92% of the trials and a point measure and measure of
variability were reported in 83% of the trials. Nine trials were
considered as having a low risk of bias6–8,31–33,35,57,59 and three trials
were considered as having a high risk of bias.34,58,60
Participants
The participants had acute LBP in two trials31,60 and chronic LBP in
11 trials6–8,31–35,57–59 (range 7 months to 110 months, based on six
trials). One trial31 included a mixed sample (acute and chronic) and
the data were presented separately. One trial60 included people with
acute LBP, although the duration of symptoms was not explicitly re-
ported. One trial8 included people with LBP for a duration of  4
weeks; however, the mean duration of symptoms was . 3 months
(ie, most had chronic LBP: 7 months in the PBMT group and 13
months in the control group) and thus the trial was included in the
meta-analysis of chronic LBP. The duration of pain in another two
trials was not reported; however, the authors claimed that all the
participants had chronic LBP.6,33
Interventions
Detailed description of the included trials’ characteristics can be
found in Table 3. The source of PBMT, parameters used, and frequency
and duration of treatment varied substantially among the trials.
Detailed specifications of the PBMT interventions are presented in
Table 4 on the eAddenda.
Low-level laser therapy was applied in most
trials.6,7,31,33–35,57–60 One trial8 used a 1,060 nm Nd-Yag laser and
another trial32 used a pad of LEDs. The light was applied in a
steady mode with direct skin contact in 10 trials.6–8,31,32,35,57–60
One trial34 used scanning mode, while another trial33 used a
combination of steady mode with direct skin contact on the spine
and scanning mode on paravertebral muscles.
All energy doses (J) were recalculated (even when provided by
authors) for each trial included and ranged from 0.06 to 31.2 J per
point (Table 4 on the eAddenda). In seven trials,7,8,31,32,57,59,60 the full
description of parameters (eg, treatment time, spot size and average
power) were not stated explicitly and so were calculated based on the
available information.
Only four trials31,35,57,58 used the recommended and assumed
adequate doses according to WALT recommendations.16 Awavelength
that was not mentioned in the guidelines was used in one trial,8 while
another trial32 used LED (also not mentioned in WALT recommen-
dations), and were thus assumed to have an inadequate dose.
Moreover, one trial59 was assumed to have an inadequate dose due a
low dose applied per point. Two trials33,34 were allocated to the
assumed inadequate dose subgroup due to the scanning mode that
was used. In scanning mode it is not possible to estimate the total



















Y Y N Y Y 7
Y Y N Y N 7
Y Y Y Y Y 8
Y N N Y Y 5
Y Y Y Y Y 9
Y N N Y Y 7
N N N N N 2
Y Y Y Y Y 7
N Y N Y Y 5
Y N N Y Y 7
Y Y N Y Y 7
Y Y N Y Y 8
Table 3
Characteristics of included trials.
Study Participants Interventionsa Outcome measuresb
Ay31 n = 80
Age (yr) = NS
Pain duration = NS
Exp = PBMT and hot pack





After treatmentc, not further specified
Basford8 n = 59
Age (yr) = 18 to 70
Pain duration (mth) . 1
Exp = PBMT




End-treatment (Week 4)c and 4 to 5 wk later
Djavid57 n = 61
Age (yr) = 20 to 60
Pain duration (mth)  3
Gr 1 = PBMT and exercise (strengthening, stretching,
mobilising, co-ordination and stabilising of the
abdominal, back, pelvic and lower limb muscles,
dependent on the clinical findings)
Gr 2 = Sham PBMT and exercise (as above)




End-treatment (Week 6)c and Week 12
Gur58 n = 75
Age (yr) = 20 to 50
Pain duration (mth)  12
Gr 1 = PBMT and exercise (lumbar flexion and extension, knee
flexion, hip adduction, and strengthening exercises
Gr 2 = Exercise (as above)




Hsieh32 n = 70
Age (yr) = 18 to 65
Pain duration (mth) . 3
Exp = PBMT
Con = Sham PBMT
 Pain
 Disability
 Quality of life
 Adverse events
End-treatment (Week 2)c
Klein59 n = 20
Age (yr) = 21 to 55
Pain duration (mth)  12
Exp = PBMT and exercise (flexion and extension exercises)




End-treatment (Week 4)c and monthly for 6 mth
Longo60 n = 120
Age (yr) = 40 to 65
Pain duration = ‘acute’, not further defined
Gr 1 = PBMT
Gr 2 = Sham PBMT
Gr 3 = Laser CO2 (wavelength = 10,600 nm; treatment time/
cm2 = 3 s; power density/diode = 1W/cm2; paravertebral
region and possible trigger points)
 Overall improvement
After 3 and 5 applications, and Months 1c
Nambi33 n = 330
Age (yr) . 18
Pain duration (mth)  3
Gr 1 = PBMT and exercise (strengthening of the abdominal
and back muscles)
Gr 2 = Exercise (as above)




 Quality of life
 Adverse events
End-treatment (Week 4)c and Months 6c and 12c
Notarnicola34 n = 60
Age (yr)  18
Pain duration (mth)  3
Exp = PBMT
Con = Tecar therapy (10 min of capacitive phase (600 kHz) and
10 min of resistive phase (450 kHz) of Tecar therapy (each
session); the power of energy in both phases was the





End-treatment (Week 2) and Weeks 6c and 10
Soriano7 n = 85
Age (yr) . 60
Pain duration (mth) . 3
Exp = PBMT
Con = Sham PBMT
 Pain
End-treatment (Week 2)c
Tantawy35 n = 45
Age (yr) = 30 to 40
Pain duration (mth) = 3
Gr 1 = PBMT and exercise (strengthening, stretching,
mobilisation, coordination, and maintaining stabilisation
of the back, abdominal, pelvic and lower extremity
muscles)
Gr 2 = Exercise (as above)
Gr 3 = Exercise (as above) and ultrasound (1 MHz; intensity =
1 W/cm2; time = 10 min; one probe; effective radiating





Toya6 n = 41
Age (yr) = NS
Pain duration = NS
Exp = PBMT
Con = Sham PBMT
 Pain
End-treatment (Day 0)c and Day 1
Con = control group, Exp = experimental group, Gr = group, PBMT = photobiomodulation therapy.
a Details of the PBMT used in each trial are presented in Table 4 on the eAddenda.
b Only the outcomes relevant to this review are listed.
c Time points considered in this systematic review.
Research 159could not be allocated in either subgroup due a lack of information
(eg, treatment time, energy and number of treated points). It was not
possible to calculate the total dose in these trials and was thus
assumed to have an unclear dose.
The frequency of PBMT treatment ranged from two to five times
per week. A single session was undertaken in one trial.6 Excluding
one trial,6 the number of sessions ranged from six to 20, but most of
them were . 10 or 12 sessions in total.Comparisons
In one trial, PBMT plus hot packs was compared with placebo plus
hot packs.31 In four trials, PBMT was compared with sham PBMT.6–8,32
In one trial, PBMT was compared with Tecar therapy (Energy Transfer
Capacitive and Resistive), which is a technological evolution of
diathermy.34 One trial57 was a three-arm trial comparing PBMT with
PBMT plus exercise and with sham PBMT plus exercise. In another
three-arm trial,58 PBMT was compared with PBMT plus exercise and
160 Tomazoni et al: Photobiomodulation therapy for low back painwith exercise alone. In one trial59 there was a comparison of PBMT
plus exercise and sham BPMT plus exercise. In another three-arm
trial,33 the interventions that were compared were exercise, PBMT
plus exercise, and PBMT plus spinal manipulation plus exercise. In a
three-arm trial35 there was a comparison of PBMT plus exercise, ex-
ercise and ultrasound plus exercise. The exercise programs in these
trials were considered to be comparable. Finally, in one trial60 with
three arms there was a comparison of PBMT, placebo and high-
intensity laser (CO2 laser, 10,600 nm).
Outcome measures
Eleven trials6–8,31–35,57–59 measured pain intensity. Only two of
them6,7 did not present the results using continuous data. One of
these trials7 reported the results as the percentage of pain relief,
categorised as poor, regular, good or excellent, and the treatment was
considered effective when the response was good or excellent. In
another trial6 pain was dichotomised as excellent, good or fair
improvement versus little or no change or exacerbation. Various in-
struments were used to measure disability: Roland Morris Disability
Questionnaire, Oswestry Disability Index and Modified Oswestry
Disability Index. Measurement of secondary outcomes was not
frequent among trials. Nine trials6–8,31–34,57,59 reported no adverse
effects. The time-points of assessments of patients ranged from
immediately after the end of one single treatment session6 to 1 year
after baseline.33 The outcome measures and measuring instruments
are presented in Table 5 on the eAddenda.
Effects of interventions
The effects on the primary outcomes for each comparison are
presented below, separated by whether the participants had acute/
subacute or chronic LBP. The effects on the secondary outcomes for
each comparison are presented in Appendix 2 on the eAddenda.
PBMT versus sham PBMT for acute/subacute LBP
Pain intensity
One trial with low risk of bias31 (assumed adequate dose)
compared PBMT plus hot packs with sham PBMT plus hot packs on
acute LBP. It provided low-quality evidence (downgraded due to
inconsistency and imprecision) that PBMT is unlikely to provide a
worthwhile benefit on pain intensity at short-term follow-up (MD
7.00, 95% CI 21.87 to 15.87, n = 40).
Disability
One trial with low risk of bias31 measured disability. It provided
low-quality evidence (downgraded due to inconsistency and impre-
cision) that PBMT did not have a worthwhile effect on disability at
short-term follow-up (MD 21.00, 95% CI 211.06 to 9.06, n = 40).
PBMT versus other treatments for acute/subacute LBP
The trial comparing PBMT with CO2 laser for acute/subacute LBP is
presented in Appendix 2 on the eAddenda.
PBMT versus sham PBMT for chronic LBP
Pain intensity
Four trials with low risk of bias6–8,32 compared PBMT versus sham
PBMT at short-term follow-up (closest to 4 weeks). Moreover, three
trials with low risk of bias compared PBMT with sham PBMT asso-
ciated with either hot packs31 or exercise57,59 also at short-term
follow-up (closest to 4 weeks).
Five trials8,31,32,57,59 measured pain intensity using continuous
scales, while two trials6,7 measured pain intensity using categorical
scales. Thus, these trials were separated into two meta-analyses
(continuous and dichotomous) to estimate the effectiveness of
PBMT compared with sham PBMT at short-term follow-up.
Included in the first meta-analysis were five trials8,31,32,57,59 that
used a visual analogue scale to measure pain intensity, with low riskof bias. They provided low-quality evidence (downgraded due to
inconsistency and imprecision) that PBMT did not have a worthwhile
effect on pain at short-term follow-up (MD 23.95, 95% CI 210.98 to
3.08, n = 230). See Figure 2a, or for a detailed forest plot see Figure 3a
on the eAddenda.
One trial7 measured painwith a visual analogue scale but reported
the results as percentage of relief. Pain was considered improved
when the pain relief evaluation was 60 to 100%. Thus, in this sys-
tematic review, we transformed the pain intensity data from this
trial7 at short-term into a categorical outcome (improved or not).
Furthermore, investigators of another trial6 also measured pain with
their own scale and provided the results as categorical data. Pain was
considered improved when graded as excellent, good or fair, but not
when it was graded as little or no change and exacerbated. These two
trials6,7 with low risk of bias and an unclear dose provided low-
quality evidence (downgraded due to inconsistency and impreci-
sion) that the effect of PBMTon pain intensity at short-term follow-up
remains very uncertain (RR 0.32, 95% CI 0.08 to 1.34, n = 126). See
Figure 2b, or for a detailed forest plot see Figure 3b on the eAddenda.
Disability
Five trials8,31,32,57,59 with low risk of bias were meta-analysed to
estimate the effect on disability in the short term. The meta-analysis
provides low-quality evidence (downgraded due to inconsistency and
imprecision) that any effect of PBMT is too small to be worthwhile
(MD 24.83, 95% CI 210.29 to 0.64, n = 230). See Figure 2c, or for a
detailed forest plot see Figure 3c on the eAddenda.
Subgroup analysis
Subgroup analyses were performed of the two trials with assumed
adequate dose of PBMT31,57 and three trials with assumed inadequate
dose.8,32,59 See Figure 2a, c and d, or for more detail see Figure 3a, c
and d on the eAddenda. The pooled effect size showed that PBMT is
unlikely to have a worthwhile effect on pain intensity at short-term
follow-up both for assumed adequate dose (MD 22.57, 95%
CI 29.67 to 4.54, n = 81) and assumed inadequate dose (MD 25.28,
95% CI 218.05 to 7.49, n = 149). Furthermore, the pooled effect size
also indicates that PBMT is unlikely to have a worthwhile effect on
disability at short-term follow-up both for assumed adequate dose
(MD25.48, 95% CI212.17 to 1.21, n = 81) and for assumed inadequate
dose (MD 24.92, 95% CI 213.31 to 3.46, n = 149). Therefore, inclusion
of only trials with adequate dosage does not appear to change the
effect of PBMT compared with sham.Effect of PBMT versus exercise for chronic LBP
Pain intensity
One trial with low risk of bias57 and one with high risk of bias58
were meta-analysed to estimate the effect of PBMT versus exercise.
Both trials measured pain intensity at short-term follow-up to provide
very low-quality evidence (downgraded due to risk of bias, inconsis-
tency and imprecision). The estimate of the between-group difference
was very imprecise (MD 22.10, 95% CI 218.71 to 14.52, n = 90). See
Figure 4a, or for a detailed forest plot see Figure 5a on the eAddenda.
Disability
The same two trials57,58 measured disability at short-term follow-
up and the meta-analysis showed that there was low-quality evi-
dence (downgraded due to risk of bias and imprecision) that PBMT
does not have any worthwhile benefit over exercise (MD 4.38, 95%
CI 21.39 to 10.15, n = 90). See Figure 4b, or for a detailed forest plot
see Figure 5b on the eAddenda.Effect of PBMT versus other treatments for chronic LBP
The trial34 comparing PBMT with Tecar therapy and the trial35
comparing PBMT with ultrasound plus exercise for chronic LBP are




















































Favours PBMT Favours sham
Figure 2. Meta-analysis of trials comparing photobiomodulation therapy (PBMT) with sham PBMT in chronic low back pain at short-term: (a) pain intensity (continuous outcome),
(b) pain intensity (dichotomous outcome), (c) disability and (d) overall improvement.
PBMT = photobiomodulation therapy.
Research 161Effect of PBMT plus exercise versus exercise for chronic LBP
Pain intensity
One trial with high risk of bias58 and two trials with low risk of
bias33,35 were included in the meta-analysis of the comparison of
PBMT plus exercise versus exercise. These three trials measured pain
intensity at short-term follow-up. They provided very low-quality
evidence (downgraded due to risk of bias, inconsistency and impre-
cision) that the estimate of the between-group difference was very
imprecise (MD 211.70, 95% CI 224.99 to 1.59, n = 300) See Figure 6a,
or for a detailed forest plot see Figure 7a on the eAddenda.
One trial with low risk of bias33 compared PBMT plus exercise
with exercise in the intermediate and long term. This constituted low
quality of evidence (downgraded due to inconsistency and impreci-
sion). There was a small and clinically unimportant effect of PBMT
plus exercise over exercise alone in decreased pain intensity in the
intermediate term (MD 23.00, 95% CI 25.33 to 20.67, n = 110) and
long term (MD 29.00, 95% CI 211.35 to 26.65, n = 110) compared
with exercise alone.
Disability
The same three trials that measured pain33,35,58 also measured
disability in the short term. The meta-analysis constituted very low-
quality evidence (downgraded due to risk of bias, inconsistency and
imprecision). Due to the wide CI, the effect of exercise as an adjunct to
exercise remaineduncertain (MD25.26, 95%CI217.50 to 6.98, n = 300).
See Figure 6b, or for adetailed forest plot see Figure7bon theeAddenda.One trial33 compared PBMT plus exercise versus exercise in the in-
termediate and long term. There was low-quality evidence (down-
gradeddue to inconsistencyand imprecision) that therewas a small and
clinically unimportant effect of PBMT as an adjunct to exercise on pain
intensity in the intermediate term (MD 23.00, 95% CI 25.33 to 20.67,
n = 110) and long term (MD 29.00, 95% CI211.35 to 26.65, n = 110).
Subgroup analysis
Subgroups were analysed to distinguish the two trials35,58 with
assumed adequate dose of PBMT from the trial33 with an assumed
inadequate dose. The pooled estimate of the two trials (onewith high58
and one with low35 risk of bias) was that adequate-dose PBMT used as
an adjunct to exercise decreased pain in the short term); unfortunately,
this estimate had enough uncertainty to make it unclear whether the
effect was clinically worthwhile or trivial (MD 218.92, 95% CI 236.44
to 21.41, n = 80). See Figure 6a, or for more detail see Figure 7a on the
eAddenda. In contrast, the pooled effect size was not statistically sig-
nificant for disability in the short term for either subgroup. See
Figure 6b, or for more detail see Figure 7b on the eAddenda.Effect of PBMT plus spinal manipulation plus exercise versus
exercise for chronic LBP
The comparison PBMT plus spinal manipulation plus exercise

















Favours PBMT Favours exercise
a b
Figure 4. Meta-analysis of trials comparing photobiomodulation therapy (PBMT) with exercise in chronic low back pain at short-term: (a) pain intensity and (b) disability.
PBMT = photobiomodulation therapy.
162 Tomazoni et al: Photobiomodulation therapy for low back painGRADE summaries
The overall quality of evidence for each outcome in each com-
parison can be seen in Table 6 on the eAddenda.Sensitivity analysis
The risk of publication bias was not assessed with funnel plots
because the power of the test was too low with , 10 trials.36 The low
number of included trials also precluded a valid analysis of the impact
from within-study risk of bias.Discussion
In general, the results showed that there was low-quality evidence
that PBMT was not better than sham for acute/subacute or chronic
LBP in the short term. Low-quality evidence suggested that PBMT plus
exercise improved pain and disability more than ultrasound plus
exercise, but the 95% CI showed uncertainty about whether this effect
was clinically worthwhile. Low-quality evidence also suggested that
PBMT plus spinal manipulation and exercise was better than exercise
alone to a moderate (and therefore clinically worthwhile) extent;
unfortunately, it was not possible to distinguish how much (if any) of
that benefit was due to PBMT, due to the uncontrolled co-
intervention (spinal manipulation). There was low-quality evidence





















Figure 6. Meta-analysis of trials comparing photobiomodulation therapy (PBMT) plus exe
disability.
PBMT = photobiomodulation therapy.Twelve randomised trials were included in this systematic review,
and although most of them presented low risk of bias,6–8,31–33,35,57,59
methods such as intention-to-treat, concealed allocation and blinding
of participants and therapists were rarely used.62 In addition, we
detected some relevant problems that decreased the quality of evi-
dence and thereby decreased confidence in the accuracy of results.
Most of the included trials had a small sample size (mean of 32
participants per group), did not describe sample size calculation and,
when described, the reported rationale was inadequate. In-
consistencies were also observed among the results of the included
trials, probably due to the great heterogeneity among their PBMT
parameters, duration and frequency of treatments, characteristics of
participants, duration of follow-up, selection of outcome measure-
ment instruments and methodological quality.
It is well accepted that the choice of PBMT parameters is crucial
for the effectiveness of the therapy19,25,63–65 because application of
doses below and/or above the recommended range have been iden-
tified as a major factor that leads to negative outcomes.63 Thus, for
the interpretation of clinical trials, it is essential to evaluate the doses
of PBMT.19,25,63–65 However, most trials included in this review
inadequately or insufficiently reported the PBMT parameters,10 which
make interpretation of the results difficult. Furthermore, the minimal
information about parameters provided in at least four trials6,7,34,60
could have led to a misleading picture, forcing caution in the data
analysis and conclusions of this systematic review. The included trials
presented extremely varied parameters. For example, the energy
doses ranged from 0.06 to 31.2 J/point, irradiation time ranged from
















rcise with exercise in chronic low back pain at short-term: (a) pain intensity and (b)
Research 163500 mW. Finally, these trials did not report considerations that sup-
ported the choice of parameters that were used and also did not
discuss the optimisation of these parameters.
A previous systematic review26 only qualitatively analysed the
included trials and observed that PBMT, especially low-level laser
therapy, was more effective than placebo, but not clinically signifi-
cant, in decreasing pain intensity in the short and intermediate term
in people with chronic LBP. Moreover, only one trial showed that
PBMT significantly improved disability compared with placebo
treatment.8 In contrast, that same systematic review26 concluded that
PBMT was not better than exercise or exercise plus placebo treat-
ment. Our results differ from the aforementioned systematic review,
which can be explained partly by the inclusion of five new trials in
our review.31–35 In addition, we observed that data extraction was
performed differently in three trials.6,7,60 For example, Youseffi-
Noraie et al26 presented data as percentages, whereas in our re-
view, we dichotomously presented pain intensity and overall
improvement as improved or not. Moreover, the duration of follow-
up considered from each included trial diverged between the sys-
tematic reviews.
Two previous systematic reviews27,28 compared laser therapy
(both low-level and high-intensity) against placebo and showed that
laser therapy was effective in decreasing pain intensity in people with
non-specific chronic LBP. However, it is important to highlight that
although these two systematic reviews suggested that the effects of
low-level laser therapy in people with chronic non-specific LBP were
evaluated, one trial that evaluated the effects of high-intensity laser
therapy was also included;66 therefore, they cannot be considered as
PBMT. In addition, unlike our systematic review, Glazov et al28
included several laser acupuncture trials. Thus, we believe that the
addition of a therapy different from PBMT may have positively
skewed the results, explaining the divergence.
Clinical practice guidelines from the American College of Physi-
cians recently recommended the use of PBMT for the treatment of
people with chronic LBP. However, this recommendation was sup-
ported by only three randomised trials,6–8 which observed that PBMT
compared with placebo decreased pain intensity in the short term in
people with chronic LBP. In contrast, our systematic review sum-
marised 12 randomised trials and comprised all available evidence to
date regarding the effects of PBMT compared with any other com-
parison groups in people with acute, subacute and chronic LBP. Unlike
what was recommended by the American College of Physicians,5 the
present review showed that the available evidence is inadequate to
support the use of PBMT in people with non-specific LBP.
In the present review, subgroup analyses investigated the ade-
quacy of PBMT dosage, based on the doses recommended by WALT.16
Subgroup analysis by dosage was challenging due to the limited
number and reporting of studies. However, it was important to
identify the limitations related to reporting of PBMT parameters in
existing trials. Among the previous systematic reviews, only one
performed this type of analysis.26 Our results corroborate those re-
ported in a study by Yousefi-Nooraie et al,26 in which the results of
subgroup analysis were the same as those of the main comparison of
PBMT versus placebo. In contrast, on comparing PBMT plus exercise
with exercise alone, the mean estimate of the subgroup analysis
suggested that using an adequate PBMT dose had a moderate effect in
decreasing pain intensity at the short-term follow-up; however, the
confidence interval did not exclude the possibility that the true effect
may not be clinically worthwhile. Also, it is important to highlight
that one trial58 with high risk of bias and one trial35 with low risk of
bias were included in the subgroup assumed to have received an
adequate dose. Thus, these results should be interpreted with further
caution because the estimates of effect may have been biased by low
methodological quality.
AlthoughWALT provides dosage guidelines, we observed that only
four included trials31,35,57,58 (33%) used the recommended andassumed adequate doses. By qualitatively analysing each of these
trials (Table 7 on the eAddenda), a clinically important effect of PBMT
for both the decrease in pain intensity and disability was found in
only one trial.35 In contrast, one trial7 used an unclear dose and the
mean estimate of the effect of PBMT was clinically important,
although the confidence interval still included clinically unimportant
effects. In addition, one trial8 that used a wavelength (1,064 nm) that
was not included in the WALT guidelines obtained a moderate and
clinically important mean estimate, but again the confidence interval
showed uncertainty. That study used a modified high-intensity laser
device (class 4) and the observed positive outcomes might have been
related to thermal sensation felt by participants. Yet, another trial32
that used LED (also not mentioned in the WALT guidelines) showed
a small and clinically unimportant effect of PBMT in decreasing
disability. Thus, we observed that in trials that showed that PBMT was
effective in improving the primary outcomes, the doses that were
used were higher than those recommended by WALT. This suggests
that increasing the PBMT dose may be beneficial in the treatment of
LBP. However, problems such as small sample size, lack of concealed
allocation and unblinded therapists decrease confidence in the ac-
curacy of this suggestion.
The qualitative analysis conducted in one trial33 showed that
the association of PBMT with exercise was effective in decreasing
pain intensity and disability in the intermediate and long term, but
the treatment effect was small and clinically unimportant. Inter-
estingly, the same trial showed that the combination of PBMT with
spinal manipulation and exercise was effective and clinically
important in decreasing pain intensity and disability in patients
with chronic LBP. These results corroborate evidence showing that
the combination of PBMT with exercise appears to potentiate the
effects of exercise in other conditions.10,66 However, although this
trial33 had a low risk of bias, items such as concealed allocation
and blinding of participants and therapists were not used. Thus,
our confidence in the accuracy of these results is low. Overall, if
adequate doses of PBMT were used, better results might be
observed from PBMT with exercise for LBP.
Strengths of this review included the use of a sensitive search
strategy using five databases and manual searches through refer-
ence lists of manuscripts, without any publication or language re-
striction on data. Moreover, two independent authors conducted
the screening of trials, data extraction and assessment of the
methodological quality, as recommended by the Cochrane Collab-
oration. Finally, the quality of evidence was carefully assessed ac-
cording to the GRADE approach. Unfortunately, after screening all
titles and abstracts, although five congress abstracts were identi-
fied, no reply was received from the authors after contacting them
via e-mail. Moreover, one trial was identified at the screening
phase that contained no contact information of the authors, and
neither the journal nor the manuscript were found after an
extensive search. Finally, we evaluated the effects of PBMT on non-
specific LBP at predetermined time points only, which potentially
left some time points uncovered.
Further trials that follow rigorous methodological quality and
adequate sample sizes are required to investigate the optimisation
of PBMT parameters in LBP.67 It is essential that the trials provide
a rationale for the choice of parameters and/or that these
parameters are optimised. In addition, the trials should investigate
the optimal PBMT dosage and ‘therapeutic window’ for a given health
condition. It is important that future trials be based on the Consoli-
dated Standard of Reporting Trials (CONSORT) to report trials and the
TIDieR checklist to increase the description of interventions.68,69
Moreover, all PBMT parameters should be described as clearly and
completely as possible, preferably as a table in the manuscript.
Finally, trials that investigate the long-term follow-up are necessary
because only two trials33,60 with this characteristic were identified in
this review.
164 Tomazoni et al: Photobiomodulation therapy for low back painOverall, there was insufficient evidence to support the use of
PBMT to decrease pain intensity and disability in people with acute/
subacute and chronic non-specific LBP.What was already known on this topic: Some clinical
practice guidelines have recommended photobiomodulation
therapy for low back pain but with limited evidence to support
this recommendation. Since the most recent systematic reviews
on the topic, photobiomodulation therapy has been defined as
non-thermal and non-ionising light therapy, and its effect on low
back pain has been assessed in additional randomised trials.
What this study adds: Based on the available evidence from
randomised trials, there is insufficient evidence to support the
use of PBMT to decrease pain intensity and disability in people
with acute/subacute and chronic non-specific LBP. Compared
with sham, it is unlikely to have a worthwhile benefit on pain or
disability, although at some time points there was insufficient
data to generate a precise estimate of its effect. Although ben-
efits were observed on some other outcomes, these estimates
were imprecise and/or based on low-quality evidence.
Footnotes: a Review Manager Version 5.3, The Nordic Cochrane
Centre, The Cochrane Collaboration, Copenhagen, Denmark.
eAddenda: Tables 2, 4, 5, 6 and 7; Figures 3, 5 and 7; and
Appendices 1 and 2 can be found online at https://doi.org/10.1016/
j.jphys.2020.06.010.
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